Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Angiotensin-Converting Activity of Tissue Kallikrein

      , , ,

      Nephron

      S. Karger AG

      Kallikrein, Kinins, Tonin

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          This study examined the ability of tissue kallikreins, purified from both rat submandibular gland (SMG) and human urine, to form angiotensin II from synthetic angiotensin I. Both kallikreins converted angiotensin I to angiotensin II at neutral pH with the following kinetic constants: SMG kallikrein, K<sub>m</sub> = 9.43×10<sup>5</sup> mol/l, K<sub>cat</sub> = 1.58 μmol/mg protein/min; human urinary kallikrein, K<sub>m</sub> = 1.71 × 10 <sup>4</sup> mol/l, K<sub>cat</sub> = 0.06 μmol/mg protein/min. These activities were not affected by angiotensin-converting enzyme (ACE) inhibitor. These results suggest that tissue kallikrein might participate in the formation of angiotensin II during administration of an ACE inhibitor.

          Related collections

          Author and article information

          Journal
          NEF
          Nephron
          10.1159/issn.1660-8151
          Nephron
          S. Karger AG
          978-3-8055-5180-9
          978-3-318-01967-4
          1660-8151
          2235-3186
          1990
          1990
          16 December 2008
          : 55
          : Suppl 1
          : 62-64
          Affiliations
          Department of Internal Medicine, Fukuoka University School of Medicine, Fukuoka, Japan
          Article
          186037 Nephron 1990;55:62–64
          10.1159/000186037
          1693176
          © 1990 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 3
          Categories
          Poster Session

          Cardiovascular Medicine, Nephrology

          Tonin, Kinins, Kallikrein

          Comments

          Comment on this article